Search
SOLACI Congress
HomeCONGRESS

CONGRESS

View Category
Structural heart disease

ACC 2021 | ATLANTIS 4D-CT: Apixaban and Sub-Clinical Thrombosis After TAVR

Indicating apixaban after transcatheter aortic valve replacement (TAVR) does not significantly reduce the risk of sub-clinical leaflet...
solaci -
Learn More
Coronary Disease

ACC 2021 | RAPID-TnT: Usefulness of High-Sensitivity Ultra-Fast Troponin T

Patients under evaluation for acute coronary syndrome (ACS) without clear ischemia signs in an electrocardiogram find no...
solaci -
Learn More
Femoropopliteal

ACC 2021 | SAFE-PAD: Paclitaxel-Eluting Devices in Peripheral Disease

This work was conducted alongside the US Food and Drug Administration (FDA) to investigate the association between...
solaci -
Learn More
Antithrombotic Anticoagulants

ACC 2021 | ATLANTIS: Apixaban After TAVR vs. Standard of Care

Adding apixaban to the treatment of patients undergoing transcatheter aortic valve replacement (TAVR) was non-superior to standard...
solaci -
Learn More
Antiplatelet

ACC 2021 | ADAPTABLE: Low Doses of Aspirin Are Equally Effective and Present Lower Bleeding Risk

Patients diagnosed with cardiovascular disease taking aspirin as secondary prevention can take lower doses and achieve the...
solaci -
Learn More
Acute coronary syndromes

ACC 2021 | TALOS-AMI: De-escalating from Ticagrelor to Clopidogrel after One Month

After one-month dual antiplatelet therapy (DAPT) with aspirin and ticagrelor, a net clinical benefit was observed when...
solaci -
Learn More
Other

ACC 2021 | Relive Renal Denervation with RADIANCE-HTN TRIO

Endovascular ultrasound renal denervation significantly reduces systolic blood pressure when compared against a sham procedure according to...
solaci -
Learn More
Acute coronary syndromes

ACC 2021 | Sacubitril/Valsartan not Superior to Ramipril after AMI

The combination sacubitril/valsartan following high-risk AMI did not reduce the risk of cardiac failure or cardiovascular risk in...
solaci -
Learn More

SOLACI is the reference organization for Latin American cardiovascular interventionism.

Last News

Endoleaks after endovascular repair of complex aortic aneurysms: always reintervene or monitor with CTA?

Dr. Juan Manuel Pérez - 0
Endovascular repair of thoracoabdominal aneurysms requiring sealing above the renal arteries, with preservation of visceral vessels using fenestrated and/or branched devices (F/B-EVAR), has become...

Is it safe to use negative chronotropic drugs early after TAVI?

Dr. Juan Manuel Pérez - 0
TAVI is associated with a relevant incidence of conduction system disturbances and the development of atrioventricular block that may require permanent pacemaker implantation. Many...

Long-Term Cardiovascular Risk in Patients With ANOCA: A Clinical Reality to Consider?

Dr. Omar Tupayachi - 0
Chronic stable angina (CSA) remains one of the most frequent reasons for referral to diagnostic coronary angiography (CAG). In a substantial proportion of these...

Institutional News

SOLACI Wishes You Happy Holidays

solaci - 0
From the heart, Happy Holidays! The Latin American Society of Interventional Cardiology wishes all its members and the medical community across the continent a very Merry Christmas...

Condolences on the passing of Cristiam Arancibia

solaci - 0
The Latin American Society of Interventional Cardiology deeply mourns the passing of Lic. Cristiam Arancibia, first Director of the Chapter of Technicians and Nurses,...

Watch Again: Pulmonary Embolism in 2025 — Risk Stratification and Novel Therapeutic Approaches

solaci - 0
Our webinar “Pulmonary Embolism in 2025: Risk Stratification and Novel Therapeutic Approaches” is now available to watch. The session took place on November 25,...

Access

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Terms of Use -Privacy Policy